Compare FOLD & PECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOLD | PECO |
|---|---|---|
| Founded | 2002 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.5B |
| IPO Year | 2007 | 2021 |
| Metric | FOLD | PECO |
|---|---|---|
| Price | $14.30 | $37.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $26.11 | ★ $38.71 |
| AVG Volume (30 Days) | ★ 7.8M | 870.6K |
| Earning Date | 02-18-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 3.44% |
| EPS Growth | N/A | ★ 37.32 |
| EPS | N/A | ★ 0.65 |
| Revenue | $598,704,000.00 | ★ $711,781,000.00 |
| Revenue This Year | $21.49 | $10.46 |
| Revenue Next Year | $18.46 | $5.30 |
| P/E Ratio | ★ N/A | $57.92 |
| Revenue Growth | ★ 21.28 | 10.73 |
| 52 Week Low | $5.51 | $32.40 |
| 52 Week High | $14.38 | $37.89 |
| Indicator | FOLD | PECO |
|---|---|---|
| Relative Strength Index (RSI) | 79.26 | 78.49 |
| Support Level | $14.30 | $34.95 |
| Resistance Level | $14.31 | $35.87 |
| Average True Range (ATR) | 0.03 | 0.65 |
| MACD | -0.13 | 0.29 |
| Stochastic Oscillator | 35.00 | 99.14 |
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interests, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on market of expertise designed to optimize property value and consistently deliver a great shopping experience.